Table 1.
Clinical characteristics of the patients stratified by LMR
| Characteristics | Total n=317 (%) | LMR
|
||
|---|---|---|---|---|
| ≤4.91 | >4.91 | P-value | ||
| Age (years) | 0.538 | |||
| ≤60 | 212 (66.9) | 138 | 74 | |
| >60 | 105 (33.1) | 72 | 33 | |
| Sex | 0.022 | |||
| Male | 205 (64.7) | 145 | 60 | |
| Female | 112 (35.3) | 65 | 47 | |
| Cycles of neoadjuvant XELOX regimen | <0.002 | |||
| 1 | 13 (4.1) | 10 | 3 | |
| 2 | 162 (51.1) | 117 | 45 | |
| 3 | 63 (19.9) | 42 | 21 | |
| 4 | 79 (24.9) | 41 | 38 | |
| Radiotherapy model | <0.002 | |||
| IMRT | 154 (48.6) | 87 | 67 | |
| 3D-CRT | 146 (46.1) | 110 | 36 | |
| Conventional RT | 17 (5.4) | 13 | 4 | |
| Radiation dose (Gy) | 0.001 | |||
| 46 | 171 (53.9) | 127 | 44 | |
| 50 | 146 (46.1) | 83 | 63 | |
| Interval from radiotherapy to surgery (days) | 0.174 | |||
| ≤49 | 210 (66.2) | 117 | 93 | |
| >49 | 107 (33.8) | 51 | 56 | |
| Tumor size (cm) | 0.133 | |||
| ≤3 | 226 (71.3) | 144 | 82 | |
| >3 | 91 (28.7) | 66 | 25 | |
| DAV (cm) | 0.176 | |||
| ≤5 | 165 (52.1) | 115 | 50 | |
| >5 | 152 (47.9) | 95 | 57 | |
| Postoperative TNM stage | <0.191 | |||
| pCR | 85 (26.8) | 53 | 32 | |
| I | 62 (19.6) | 40 | 22 | |
| IIA | 59 (18.6) | 35 | 24 | |
| IIB | 42 (13.2) | 35 | 7 | |
| IIIA | 16 (5.0) | 7 | 9 | |
| IIIB | 48 (15.1) | 36 | 12 | |
| IIIC | 5 (2.0) | 3 | 2 | |
| TRG | 0.097 | |||
| 1–2 | 160 (50.5) | 99 | 61 | |
| 3–5 | 157 (49.5) | 111 | 46 | |
| Surgical type | <0.064 | |||
| Anterior resection | 203 (64.0) | 125 | 78 | |
| Abdominal perineal resection | 106 (33.4) | 79 | 27 | |
| Others | 8 (2.5) | 6 | 2 | |
| Tumor differentiation | 0.841 | |||
| Well differentiated | 34 (10.7) | 22 | 12 | |
| Moderately or poorly differentiated | 283 (89.3) | 188 | 95 | |
| Pre-CRT CEA (ng/mL) | 0.528 | |||
| ≤5 | 161 (50.8) | 104 | 57 | |
| >5 | 156 (49.2) | 106 | 50 | |
| Pre-CRT CA199 (U/mL) | 0.120 | |||
| ≤35 | 264 (83.3) | 170 | 94 | |
| >35 | 53 (16.7) | 40 | 13 | |
Note: P-value, the correlation between clinical–pathological parameters and LMR was assessed by the chi-square test or Fisher’s exact test.
Abbreviations: LMR, lymphocyte-to-monocyte ratio; XELOX, oxaliplatin 130 mg/m2 administered intravenously on Day 1 and capecitabine administered orally 1,000 mg/m2 twice daily on Days 1–14 for a 3-week cycle; IMRT, intensity-modulated radiation therapy; 3D-CRT, 3-dimensional conformal radiation therapy; RT, radiotherapy; DAV, distance of inferior tumor margin from the anal verge; TNM, tumor node metastasis; pCR, pathologic complete response; TRG, tumor regression grade; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen; CA199, cancer antigen 199.